You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

aGVHD, cGVHD, PT-CY

Showing 1 - 25 of 828
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

The Optimization of Haploidentical Hematopoietic Stem Cell

Not yet recruiting
  • Hematological Malignancy
  • ATG
  • Post-transplantation cyclophosphamide
  • Beijing, Beijing, China
    People's Hospital of Peking University
Nov 28, 2022

GVHD, Acute Trial in Shanghai (PT-CY-FK +/-ATG)

Completed
  • GVHD, Acute
  • PT-CY-FK +/-ATG
  • Shanghai, Shanghai, China
    Rui Jin Hospital
May 19, 2021

Cytomegalovirus Infection After HSCT and PT-CY as GVHD

Completed
  • CMV Infection
    • Malaga, Spain
      Maria Jesus Pascual
    Mar 30, 2022

    Severe Aplastic Anemia Trial (Busulfan, Flu/Cy/ATG or Cy/ATG)

    Not yet recruiting
    • Severe Aplastic Anemia
    • (no location specified)
    Oct 1, 2023

    Stem Cell Transplantation Trial in Houston (Fludarabine, Dexamethasone, Cyclophosphamide)

    Not yet recruiting
    • Stem Cell Transplantation
    • Houston, Texas
      M D Anderson Cancer Center
    May 4, 2022

    Leukemia, Stem Cell Transplant, Cord Blood Trial in Guangzhou (applying of FLU+CY post-HSCT)

    Recruiting
    • Leukemia
    • +2 more
    • applying of FLU+CY post-HSCT
    • Guangzhou, Guangdong, China
      Nanfang Hospital
    Nov 23, 2023

    Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +12 more
    • Tucson, Arizona
      The University of Arizona Cancer Center
    Dec 13, 2022

    Hematological Malignancies Trial (Allogeneic T cell progenitors, cultured ex-vivo)

    Not yet recruiting
    • Hematological Malignancies
    • Allogeneic T cell progenitors, cultured ex-vivo
    • (no location specified)
    Mar 2, 2023

    Relapse Rate After Allo-HSCT Trial in Shanghai (Flu-Bu-Mel)

    Active, not recruiting
    • Relapse Rate After Allo-HSCT
    • Shanghai, China
    • +1 more
    Jun 1, 2021

    Hematologic Malignancy Trial (Cyclophosphamid, ATG)

    Not yet recruiting
    • Hematologic Malignancy
    • (no location specified)
    Oct 29, 2023

    Refractory Acute Myeloid Leukemia Trial in Shanghai (Aza-Ven-allo-HSCT)

    Recruiting
    • Refractory Acute Myeloid Leukemia
    • Shanghai, China
    • +2 more
    May 27, 2021

    Peripheral Blood Stem Cell Transplantation Trial in Beijing (Ruxolitinib combined with Chidamide.)

    Recruiting
    • Peripheral Blood Stem Cell Transplantation
    • Ruxolitinib combined with Chidamide.
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Oct 20, 2021

    GVHD, Acute Stem Cell Transplant Complications Trial in Chendu (Ruxolitinib)

    Not yet recruiting
    • GVHD
    • Acute Stem Cell Transplant Complications
    • Chendu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 3, 2023

    Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

    Recruiting
    • Safety and Efficacy
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Sep 27, 2023

    Mesenchymal Stem Cells Trial in Shapingba (Mesenchymal Stem Cells (MSCs))

    Recruiting
    • Mesenchymal Stem Cells
    • Mesenchymal Stem Cells (MSCs)
    • Shapingba, Chongqing, China
      Xinqiao Hospital
    Nov 24, 2023

    Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

    Not yet recruiting
    • Leukemia, Lymphoid
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Oct 3, 2023

    Acute Myeloid Leukemia (AML) Trial in Israel, Italy (Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine)

    Completed
    • Acute Myeloid Leukemia (AML)
    • Busulphan plus Cyclophosphamide
    • Busulphan plus Fludarabine
    • Tel Hashomer, Israel
    • +25 more
    Aug 19, 2021

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA Trial (Ruxolitinib 5 MG BID Oral Tablet)

    Not yet recruiting
    • The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
    • Ruxolitinib 5 MG BID Oral Tablet
    • (no location specified)
    Jun 13, 2023

    Chronic GVHD Trial in Duarte (Belumosudil, Placebo, Prednisone)

    Recruiting
    • Chronic Graft Versus Host Disease
    • Duarte, California
      City of Hope Site Number : 8400001
    Nov 23, 2023

    Hematopoietic Stem Cells Trial in Worldwide (Vedolizumab, Vedolizumab Placebo)

    Completed
    • Hematopoietic Stem Cells
    • Birmingham, Alabama
    • +138 more
    Nov 2, 2022

    Transplant-Related Disorder Trial in Tianjin (Ruxolitinib)

    Recruiting
    • Transplant-Related Disorder
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jan 28, 2023

    Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia Trial

    Not yet recruiting
    • Chronic Graft-versus-Host-Disease
    • +4 more
      • (no location specified)
      Jan 11, 2023

      Clinical and Biological Factors Determining Outcomes in Chronic

      Recruiting
      • Chronic Graft vs Host Disease
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        Aug 24, 2022

        Ibrutinib in Steroid Dependent/Refractory cGVHD Participants

        Recruiting
        • Chronic Graft vs Host Disease
          • Bucheon-Si, Korea, Republic of
          • +9 more
          Jan 27, 2023

          Chronic GVHD Trial in Bethesda, Saint Louis (Ibrutinib)

          Recruiting
          • Chronic GVHD
          • Bethesda, Maryland
          • +1 more
          Jan 26, 2023